Save this page
Save this page

My Saved Pages

  • Saved page.

My Saved Courses

  • Saved page.

Recently visited

  • Saved page.

Dr Alison Nordon


Pure and Applied Chemistry


Near-infrared hyperspectral imaging for non-destructive classification of commercial tea products
Mishra Puneet, Nordon Alison, Tschannerl Julius, Lian Guoping, Redfern Sally, Marshall Stephen
Journal of Food Engineering, (2018)
SABRE hyperpolarization enables high-sensitivity 1H and 13C benchtop NMR spectroscopy
Richardson Peter M., Parrott Andrew J., Semenova Olga, Nordon Alison, Duckett Simon B., Halse Meghan E.
Analyst, (2018)
Investigation of IR and Raman spectra of species present in formaldehyde-water-methanol systems
Gaca-Zając Katarzyna Z., Smith Benjamin R., Nordon Alison, Fletcher Ashleigh J., Johnston Karen, Sefcik Jan
Vibrational Spectroscopy, (2018)
Enabling precision manufacturing of active pharmaceutical ingredients : workflow for seeded cooling continuous crystallisation
Brown Cameron J., McGlone Thomas, Yerdelen Stephanie, Srirambhatla Vijay, Mabbott Fraser, Gurung Rajesh, Briuglia Maria L., Ahmed Bilal, Polyzois Hector, McGinty John, Perciballi Francesca, Fysikopoulos Dimitris, Macfhionnghaile Pól, Siddique Humera, Raval Vishal, Harrington Tomás S., Vassileiou Antony, Robertson Murray, Prasad Elke, Johnston Andrea, Johnston Blair, Nordon Alison, Srai Jagjit, Halbert Gavin, Ter Horst Joop H., Price Chris J., Rielly Chris D., Sefcik Jan, Florence Alastair J.
Molecular Systems Design & Engineering, (2018)
Automated weighted outlier detection technique for multivariate data
Thennadil Suresh N., Dewar Mark, Herdsman Craig, Nordon Alison, Becker Edo
Control Engineering Practice Vol 70, pp. 40-49, (2018)
A simple hand-held magnet array for efficient and reproducible SABRE hyperpolarisation using manual sample shaking
Richardson Peter M., Jackson Scott, Parrott Andrew, Nordon Alison, Duckett Simon B., Halse Meghan E.
Magnetic Resonance in Chemistry, pp. 1-18, (2017)

more publications

Professional activities

EuroPACT 2014
PhD examiner
External Examiner
Royal Society International Scientific Seminar on Nanomaterials by Design
Invited speaker
2nd Nordic Conference on Vibrational Spectroscopy
Invited speaker
SciX 2013
IRDG meeting Sept 2013
Invited speaker

more professional activities


Doctoral Training Partnership (DTP - University of Strathclyde) | McFarlan, Catriona
Nordon, Alison (Principal Investigator) Littlejohn, David (Co-investigator) McFarlan, Catriona (Research Co-investigator)
Period 01-Oct-2015 - 01-Apr-2019
Doctoral Training Centre In Continuous Manufacturing And Crystallisation | Lothian, Joanna Louise
Nordon, Alison (Principal Investigator) Littlejohn, David (Co-investigator)
Period 01-Apr-2013 - 01-Feb-2018
Industrial Case Account 2014 | Ingram, Marcus
Gachagan, Anthony (Principal Investigator) Nordon, Alison (Co-investigator) Ingram, Marcus (Research Co-investigator)
Period 01-Oct-2015 - 01-Apr-2019
Industrial support for EPSRC ICASE Award for Advanced Ultrasonic Array Imaging | Ingram, Marcus
Gachagan, Anthony (Principal Investigator) Nordon, Alison (Co-investigator) Ingram, Marcus (Research Co-investigator)
Period 01-Oct-2015 - 01-Apr-2019
Future Continuous Manufacturing and Advanced Crystallisation Research Hub (CMAC Hub)
Florence, Alastair (Principal Investigator) Halbert, Gavin (Co-investigator) Johnston, Blair (Co-investigator) Nordon, Alison (Co-investigator) Price, Chris John (Co-investigator) Sefcik, Jan (Co-investigator) Ter Horst, Joop (Co-investigator)
"Our Hub research is driven by the societal need to produce medicines and materials for modern living through novel manufacturing processes. The enormous value of the industries manufacturing these high value products is estimated to generate £50 billion p.a. in the UK economy. To ensure international competitiveness for this huge UK industry we must urgently create new approaches for the rapid design of these systems, controlling how molecules self-assemble into small crystals, in order to best formulate and deliver these for patient and customer. We must also develop the engineering tools, process operations and control methods to manufacture these products in a resource-efficient way, while delivering the highest quality materials. Changing the way in which these materials are made, from what is called batch crystallisation (using large volume tanks) to continuous crystallisation (a more dynamic, flowing process), gives many advantages, including smaller facilities, more efficient use of expensive ingredients such as solvents, reducing energy requirements, capital investment, working capital, minimising risk and variation and, crucially, improving control over the quality and performance of the particles making them more suitable for formulation into final products. The vision is to quickly and reliably design a process to manufacture a given material into the ideal particle using an efficient continuous process, and ensure its effective delivery to the consumer. This will bring precision medicines and other highly customisable projects to market more quickly. An exemplar is the hubs exciting innovation partnership with Cancer Research UK. Our research will develop robust design procedures for rapid development of new particulate products and innovative processes, integrate crystallisation and formulation to eliminate processing steps and develop reconfiguration strategies for flexible production. This will accelerate innovation towards redistributed anufacturing, more personalisation of products, and manufacturing closer to the patient/customer. We will develop a modular MicroFactory for integrated particle engineering, coupled with a fully integrated, computer-modelling approach to guide the design of processes and materials at molecule, particle and formulation levels. This will help optimise what we call the patient-centric supply chain and provide customisable products. We will make greater use of targeted experimental design, prediction and advanced computer simulation of new formulated materials, to control and optimise the processes to manufacture them. Our talented team of scientists will use the outstanding capabilities in the award winning £34m CMAC National Facility at Strathclyde and across our 6 leading university spokes (Bath, Cambridge, Imperial, Leeds, Loughborough, Sheffield). This builds on existing foundations independently recognised by global industry as 'exemplary collaboration between industry, academia and government which represents the future of pharmaceutical manufacturing and supply chain framework'. Our vision will be translated from research into industry through partnership and co-investment of £31m. This includes 10 of world's largest pharmaceutical companies (eg AstraZeneca, GSK), chemicals and food companies (Syngenta, Croda, Mars) and 19 key technology companies (Siemens, 15 SMEs) Together, with innovation spokes eg Catapult (CPI) we aim to provide the UK with the most advanced, integrated capabilities to deliver continuous manufacture, leading to better materials, better value, more sustainable and flexible processes and better health and well-being for the people of the UK and worldwide. CMAC will create future competitive advantage for the UK in medicines manufacturing and chemicals sector and is strongly supported by industry / government bodies, positioning the UK as the investment location choice for future investments in research and manufacturing."
Period 01-Jan-2017 - 31-Dec-2023
Collaborative Training Account | WILSDON, David
Nordon, Alison (Principal Investigator)
Period 01-Nov-2008 - 23-May-2013

more projects


Pure and Applied Chemistry
Royal College Building

Location Map

View University of Strathclyde in a larger map